-
CICON15 Report from Day 3
Highlights from Day 3 of the inaugural International Cancer Immunotherapy Conference.
-
CICON15 Report from Day 2
Highlights from Day 2 of the inaugural International Cancer Immunotherapy Conference.
-
CICON15 Report from Day 1
Highlights from Day 1 of the inaugural International Cancer Immunotherapy Conference.
-
CRI to Co-Host Inaugural International Cancer Immunotherapy Conference
The 4-day “go-to” meeting for scientists, clinicians, regulators, drug developers, and patient advocates begins this week.
-
CRI’s James Allison to Receive Prestigious Lasker Award
The Lasker Foundation announced today that James P. Allison, PhD, director of CRI’s Scientific Advisory Council, is…
-
New Study Suggests a Common Heart Medication Could Help Cancer Patients Live Longer
A new study published yesterday in the journal Cancer suggests that a common medication known as…
-
Jimmy Carter to Receive Immunotherapy for Melanoma
The former president will receive a drug called pembrolizumab, a PD-1-blocking antibody.
-
European Regulators Approve Pembrolizumab (Keytruda) as First-line Treatment of Advanced Melanoma
The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.
-
Phase 3 Trial Shows Nivolumab Improves Survival in Advanced Kidney Cancer
The trial ended early because data showed that patients lived longer on nivolumab compared to the standard-of-care…
